Lucid Diagnostics

LUCD · NASDAQ

$0.3519−$0.0255 (−6.76%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $0.3774

LUCD analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $4.08 (+1059.4% upside)

Low: $2.02
Now: $0.3519
High: $9.98

Upgrades and downgrades

The latest rating actions, newest first

LUCD analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Aug 27, 2026	Maintains	Buy	$9.25 → $9.50	28%
BTIG	Aug 17, 2026	Maintains	Buy	$2.50	54%
Ascendiant Capital	Jun 8, 2026	Maintains	Buy	$9.00 → $9.25	28%
Maxim Group	May 15, 2026	Maintains	Buy	$3.00 → $2.00	26%
BTIG	May 15, 2026	Maintains	Buy	$2.50	54%
Ascendiant Capital	Apr 9, 2026	Maintains	Buy	$8.25 → $9.00	28%
BTIG	Mar 30, 2026	Maintains	Buy	$2.50	54%
Needham	Mar 26, 2026	Maintains	Buy	$3.00	45%
Ascendiant Capital	Dec 10, 2025	Maintains	Buy	$8.00 → $8.25	28%
Needham	Nov 13, 2025	Maintains	Buy	$3.00	45%

The case for and against

Updated Oct 21, 2026

Bull case

Lucid Diagnostics is attractive fundamentally because EsoGuard addresses a large, underpenetrated screening need in tens of millions of GERD patients, with an estimated U.S. market opportunity of about $2 billion and strong clinical evidence, including a 99% NPV and broad guideline inclusion from ACG, AGA, and NCCN in March 2025. Its reimbursement outlook is improving after the September 4, 2025 CAC meeting, where 11 clinicians gave unanimously positive support for Medicare coverage, while the Concert LBM win and adoption by three health plans validate commercial demand and could open ~10 million covered lives over time. Financially, Q2 revenue was $1.5 million, up 27% year over year, cash was $33.4 million after an $18 million stock raise, and management believes liquidity extends into mid-2027, supporting execution.

Bear case

Lucid Diagnostics is a commercial-stage company whose fundamentals remain weak because adoption is still uneven, with tests processed falling to 2,770 in Q2 from 3,177 in Q1 and revenue only $1.3 million in Q1 2026 versus a $10.5 million pro forma net loss. Its top line is further constrained by deferred revenue recognition until cash is collected, leaving only an estimated $40 million to $45 million in potential backlog rather than immediate revenue, while commercialization is still in early days. Although the addressable market is large, management lowered its 2026 revenue estimate to $6.1 million and its 2027 estimate to $23 million, underscoring slower-than-expected payer traction and execution risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.